Skip to main content
AAN.com
Brief Communications
November 12, 2002

N-acetylcysteine and Unverricht–Lundborg disease Variable response and possible side effects

November 12, 2002 issue
59 (9) 1447-1449

Abstract

Serum glutathione levels were assessed in a patient with genetically proven Unverricht–Lundborg disease (ULD) before and during treatment with the antioxidant N-acetylcysteine (NAC). Glutathione levels were low before treatment, and increased during treatment. This increase was mirrored by an improvement in seizures, but not in myoclonus or ataxia. Three other patients with clinically determined ULD showed a variable response and some notable side effects during treatment with NAC.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Lehesjoki AE, Koskiniemi M. Clinical features and genetics of progressive myoclonus epilepsy of the Unverricht-Lundborg type. Ann Med . 1998; 30: 474–480.
2.
Hurd RW, Wilder BJ, Helveston WR, Uthman BM. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology. 1996; 47: 1264–1268.
3.
Ben-Menachem E, Kyllerman M, Marklund S. Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res . 2000; 40: 33–39.
4.
Selwa LM. N-acetylcysteine therapy for Unverricht-Lundborg disease. Neurology . 1999; 52: 426–427.
5.
Hargreaves IP, Lee PJ, Briddon A. Homocysteine and cysteine-albumin binding in homocystinuria: assessment of cysteine status and implications for glutathione synthesis. Amino Acids 2002 (in press).
6.
Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature . 1997; 386: 847–851.
7.
Lieuallen K, Pennacchio LA, Park M, Myers RM, Lennon GG. Cystatin B-deficient mice have increased expression of apoptosis and glial activation genes. Hum Mol Genet . 2001; 10: 1867–1871.
8.
Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J . 2001; 20: 4629–4633.
9.
Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet . 1998; 20: 251–258.
10.
Feghali JG, Liu W, Van De Water TR. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope . 2001; 111: 1147–1155.

Information & Authors

Information

Published In

Neurology®
Volume 59Number 9November 12, 2002
Pages: 1447-1449
PubMed: 12427904

Publication History

Received: April 1, 2002
Accepted: July 10, 2002
Published online: November 12, 2002
Published in print: November 12, 2002

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

M.J.J. Edwards, MRCP
From Sobell Department of Motor Neuroscience and Movement Disorders (M.J.J. Edwards and Drs. Ramachandran and Bhatia) and Department of Clinical Epilepsy (Dr. Sisodiya), Institute of Neurology, University College London, Queen Square; Neurometabolic Unit (Drs. Hargreaves and Heales), Department of Clinical Biochemistry, National Hospital For Neurology and Neurosurgery; and Department of Clinical Electrophysiology (Dr. Jones), National Hospital For Neurology, London, UK.
I.P. Hargreaves, PhD
From Sobell Department of Motor Neuroscience and Movement Disorders (M.J.J. Edwards and Drs. Ramachandran and Bhatia) and Department of Clinical Epilepsy (Dr. Sisodiya), Institute of Neurology, University College London, Queen Square; Neurometabolic Unit (Drs. Hargreaves and Heales), Department of Clinical Biochemistry, National Hospital For Neurology and Neurosurgery; and Department of Clinical Electrophysiology (Dr. Jones), National Hospital For Neurology, London, UK.
S.J.R. Heales, PhD
From Sobell Department of Motor Neuroscience and Movement Disorders (M.J.J. Edwards and Drs. Ramachandran and Bhatia) and Department of Clinical Epilepsy (Dr. Sisodiya), Institute of Neurology, University College London, Queen Square; Neurometabolic Unit (Drs. Hargreaves and Heales), Department of Clinical Biochemistry, National Hospital For Neurology and Neurosurgery; and Department of Clinical Electrophysiology (Dr. Jones), National Hospital For Neurology, London, UK.
S.J. Jones, PhD
From Sobell Department of Motor Neuroscience and Movement Disorders (M.J.J. Edwards and Drs. Ramachandran and Bhatia) and Department of Clinical Epilepsy (Dr. Sisodiya), Institute of Neurology, University College London, Queen Square; Neurometabolic Unit (Drs. Hargreaves and Heales), Department of Clinical Biochemistry, National Hospital For Neurology and Neurosurgery; and Department of Clinical Electrophysiology (Dr. Jones), National Hospital For Neurology, London, UK.
V. Ramachandran, MD
From Sobell Department of Motor Neuroscience and Movement Disorders (M.J.J. Edwards and Drs. Ramachandran and Bhatia) and Department of Clinical Epilepsy (Dr. Sisodiya), Institute of Neurology, University College London, Queen Square; Neurometabolic Unit (Drs. Hargreaves and Heales), Department of Clinical Biochemistry, National Hospital For Neurology and Neurosurgery; and Department of Clinical Electrophysiology (Dr. Jones), National Hospital For Neurology, London, UK.
K.P. Bhatia, FRCP
From Sobell Department of Motor Neuroscience and Movement Disorders (M.J.J. Edwards and Drs. Ramachandran and Bhatia) and Department of Clinical Epilepsy (Dr. Sisodiya), Institute of Neurology, University College London, Queen Square; Neurometabolic Unit (Drs. Hargreaves and Heales), Department of Clinical Biochemistry, National Hospital For Neurology and Neurosurgery; and Department of Clinical Electrophysiology (Dr. Jones), National Hospital For Neurology, London, UK.
S. Sisodiya, PhD
From Sobell Department of Motor Neuroscience and Movement Disorders (M.J.J. Edwards and Drs. Ramachandran and Bhatia) and Department of Clinical Epilepsy (Dr. Sisodiya), Institute of Neurology, University College London, Queen Square; Neurometabolic Unit (Drs. Hargreaves and Heales), Department of Clinical Biochemistry, National Hospital For Neurology and Neurosurgery; and Department of Clinical Electrophysiology (Dr. Jones), National Hospital For Neurology, London, UK.

Notes

Address correspondence and reprint requests to Dr. K. Bhatia, Sobell Dept. of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London, UK WC1N 3BG; e-mail: [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Molecular and cellular processes underlying Unverricht-Lundborg disease—prospects for early interventions and a cure, Exploration of Neuroscience, 3, 4, (295-308), (2024).https://doi.org/10.37349/en.2024.00051
    Crossref
  2. Association between composite dietary antioxidant index and epilepsy in American population: a cross-sectional study from NHANES, BMC Public Health, 24, 1, (2024).https://doi.org/10.1186/s12889-024-19794-y
    Crossref
  3. N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy, Molecular Neurobiology, 59, 5, (2702-2714), (2022).https://doi.org/10.1007/s12035-021-02720-3
    Crossref
  4. Altered Expression of Peroxiredoxins in Mouse Model of Progressive Myoclonus Epilepsy upon LPS-Induced Neuroinflammation, Antioxidants, 10, 3, (357), (2021).https://doi.org/10.3390/antiox10030357
    Crossref
  5. Myoclonus, Principles and Practice of Movement Disorders, (495-512.e7), (2021).https://doi.org/10.1016/B978-0-323-31071-0.00018-4
    Crossref
  6. Progressive Myoclonic Epilepsies, Handbook of the Cerebellum and Cerebellar Disorders, (2193-2228), (2021).https://doi.org/10.1007/978-3-030-23810-0_89
    Crossref
  7. Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines, Current Opinion in Pediatrics, 32, 6, (707-718), (2020).https://doi.org/10.1097/MOP.0000000000000954
    Crossref
  8. Progressive Myoclonic Epilepsies, Handbook of the Cerebellum and Cerebellar Disorders, (1-37), (2020).https://doi.org/10.1007/978-3-319-97911-3_89-2
    Crossref
  9. Unverricht-Lundborg disease: Clinical course and seizure management based on the experience of polish centers, Seizure, 69, (87-91), (2019).https://doi.org/10.1016/j.seizure.2019.04.008
    Crossref
  10. Acute and chronic neurological consequences of early-life Zika virus infection in mice, Science Translational Medicine, 10, 444, (2018).https://doi.org/10.1126/scitranslmed.aar2749
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share